© 2024 © 2020 Genprex Inc. All Rights Reserved.
Pre-clinical study results show TUSC2 overexpression reduces colony formation, neurosphere formation and promotes apoptosis in vitro, and suppresses tumor growth in vivo
Two Featured Presentations will Highlight Potential of TUSC2 Immunogene Therapy to Enhance Chemo-Immune Combination Treatments and Overcome Resistance to Osimertinib
The study highlights the possibility that TUSC2 may also be effective in thyroid cancer therapy and adds to the growing body of research on TUSC2 beyond the non-small lung cell cancer indication the Company is initially pursuing
The company announced a registered direct offering of 3,167,986 shares of its common stock at a price to the public of $0.40 per share, for gross proceeds of approximately $1.26 million prior to deduction of commissions and offering expenses payable by Genprex.
Genprex recently announced that independent researchers found that company’s TUSC2 (tumor suppressor candidate 2) prevented tumor growth in triple-negative breast cancer (TNBC). These independent researchers have no affiliation with Genprex.